Publication bias, data ownership, and the funding effect in science: Threats to the integrity of biomedical research

Rescuing Science from Politics: Regulation and the Distortion of Scientific Research

Volumn , Issue , 2006, Pages 61-85

  Krimsky, Sheldon ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926998201     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511751776.006     Document Type: Chapter

References (40)

1. Charles Pierce, "The Fixation of Belief," Popular Science Monthly 12 (Nov. 1877): 1-15.
2. Horace Freeland Judson, The Great Betrayal (New York: Harcourt, 2004), 242.
3. Jennifer Washburn, University, Inc. (New York: Basic Books, 2005), 62.
4. Terrence Monmaney, "Marshal's Hunch: Annals of Medicine," New Yorker (Sept. 20, 1993): 64-72.
5. Karl R. Popper, The Logic of Scientific Discovery (New York: Harper, 1959), 3.
6. Karl R. Popper, Conjectures and Refutations: The Growth of Scientific Knowledge, 54.
7. John Ziman, Real Science (Cambridge, UK: Cambridge University Press, 2000), 98.
8. Wayne Kondro and Barbara Sibbald, "Drug Company Experts Advised Staff to Withhold Data about SSRI Use in Children," Canadian Medical Association Journal 170, no. 5 (2004): 783.
9. Laurence Hirsch, "Randomized Clinical Trials: What Gets Published, and When?" Canadian Medical Association Journal 170, no. 4 (2004): 481.
10. Pharmaceutical Research and Manufacturers of America, "Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results," 22-3 (June 30, 2004) (available at http://www.phrma.org/publications/publications//2004--06--30.1035.pdf).
11. Eric G. Campbell et al., "Managing the Triple Helix in the Life Sciences," Issues in Science and Technology 21, no. 2 (2005): 50
12. Richard A. Knox, "Biomedical Results Often Are Withheld: Study Examines Researchers' Financial Links to Corporations," Boston Globe, April 16, 1997, sec A.
13. Robert Steinbrook, "Gag Clauses in Clinical-Trial Agreements," New England Journal of Medicine 352, no. 21 (2005): 2160-2.
14. Drummond Rennie, "Thyroid Storm," Journal of the American Medical Association 277, no. 15 (1997): 1238-43.
15. Jon Thompson et al., The Olivieri Report (Toronto: James Lorimer, 2001).
16. Robert K. Merton, "Science and the Social Order," Philosophy of Science 5 (1938): 321-37.
17. Ziman. Real Science, 174.
18. David Orentlicher and Michael K. Hehir II, "Advertising Policies ofMedical Journals: Conflicts of Interest for Journal Editors and Professional Societies," Journal of Law, Medicine and Ethics 27, no. 2 (1999): 113-21.
19. Jim Giles, "Journals Lack Explicit Policies for Separating Eds from Ads," Nature 434, no. 7033 (2005): 549.
20. Owen Dyer, "Journal Rejects Article after Objections from Marketing Department," British Medical Journal 328, no. 7434 (2004): 244.
21. S. Sussman, "Conflicts of Interest Drug Advertising Corrupts Journals," British Medical Journal 308, no. 6939 (1994): 1301.
22. Justin E. Bekelman et al., "Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review," Journal of the American Medical Association 289, no. 4 (2003): 454-65.
23. World Health Organization, Committee of Experts on Tobacco Industry Documents, Tobacco Company Strategies to Undermine Tobacco Control Activities at theWorld Health Organization (July 2000) (available at http://www.who.int/genevahearings/inquiry.html).
24. Frederick S. von Saal and Clause Hughes, "An Extensive New Literature Concerning Low-Dose Effects of Bisphenol A Shows the Need for a New Risk Assessment," Environmental Health Perspectives Online (April 13, 2005).
25. Shannon Brownlee, "Doctors without Borders: Why You Can't Trust Medical Journals Anymore," Washington Monthly 36, no. 4 (2004): 38.
26. Michelle M. Mello et al., "AcademicMedical Centers' Standards for Clinical-Trial Agreements with Industry," New England Journal of Medicine 352, no. 21 (2005): 2202-10.
27. Richard Friedman, "What You Do Know Can't Hurt You," New York Times, Aug. 12, 2003
28. Jeanne Lenzer, "FDA to Review 'Missing' Drug Company Documents," British Medical Journal 330, no. 7481 (2005): 7.
29. Dorothy S. Zinberg, "Cautionary Tale," Science 273, no. 5274 (1996): 411.
30. Eric Manheimer and Diana Anderson, "Survey of Public Information about Ongoing Clinical Trials Funded by Industry: Evaluation of Completeness and Accessibility," British Medical Journal 325, no. 7363 (2002): 528-31.
31. Catherine De Angelis et al., "Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors," New England Journal of Medicine 351, no. 12 (2004): 1250-1.
32. http://www.oag.state.ny.us/press/2004/aug/aug26a 04.html
33. Sheldon Krimsky, Science and the Private Interest (Lanham, MD: Rowman and Littlefield, 2003), 227.
34. Marcia Angell, The Truth about the Drug Companies (New York: Random House, 2004), 245.
35. Ames Gross, "Regulatory Changes in Japan's Pharmaceutical Industry," Pacific Bridge Medical (Nov. 1998) (available at http://www.pacificbridgemedical.com/publications/html/JapanNov98.htm).
36. Catherine D. DeAngelis, "Conflict of Interest and the Public Trust," Journal of the American Medical Association 284, no. 17 (2000): 2237-8.
37. Philip Campbell, "Declaration of Financial Interests: Introducing a New Policy for Authors of Research Papers in Nature and Nature Journals," Nature 412, no. 6849 (2001): 751.
38. George N. Papanikolaou et al., "Reporting of Conflicts of Interest in Guidelines of Preventive and Therapeutic Interventions,"BMCMedical Research Methodology 1, no. 3 (2001) (available at http://www.biomedcentral.com/1471--2288/1/3).
39. Sara Schroter et al., "Does the Type of Competing Interest Statement Affect Readers' Perceptions of the Credibility of Research? Randomised Trial," British Medical Journal 328, no. 7442 (2004): 742-3.
40. Sheryl Gay Stolberg, "Study Says Clinical Guides Often Hide Ties of Doctors," New York Times, Feb. 6, 2002